Resistance to immunotherapy: The elusive routes of immune escape
Achieving a durable clinical response is the ultimate goal in immuno-oncology clinical trials. With immunotherapies showing long-lasting, unprecedented responses in cancer indications such as melanoma and Non-Small Cell Lung Cancer (NSCLC), these immune-boosting drugs seem to be displaying genuine advancesREAD MORE
Is timing everything?
Unlike targeted therapies, there tends to be general agreement that it is unlikely that a single predictive biomarker in tumor biopsies will be found for determining response to immunotherapies.READ MORE
The importance of cellular neoantigens for immuno-oncology in virus-associated cancers
Approximately 12% of human cancers are associated with viral infection, including a majority of cervical cancers, Merkel cell carcinomas, and oropharyngeal cancer cases, along with significant proportions of other head and neck cancers and hepatocellular carcinomas.READ MORE
Combination therapies on the rise: Reflections from Immunotherapy World 2017
Back in October of 2016, Christelle Johnson provided an excellent blog, The state of Combination Therapies in Immuno-Oncology. This emphasis on combination strategies continues to resonate throughout the scientific community and has been highlighted at several recent conferences.READ MORE
Neoantigen discovery: Overcoming the challenges of neoantigen prediction
At Personalis, we recognize the challenges of neoantigen prediction and are working to address each of them. Our current pipeline (see Figure 1) is designed to accurately rank neoantigens using DNA and RNA sequencing data derived from the analytically-validated, augmentedREAD MORE